Effectiveness of tocilizumab in a COVID-19 patient with cytokine release syndrome

---

Atıf İçin Kopyala

USLU S.

European Journal of Case Reports in Internal Medicine, cilt.7, sa.6, 2020 (Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 7 Sayı: 6
• Basım Tarihi: 2020
• Doi Numarası: 10.12890/2020_001731
• Dergi Adı: European Journal of Case Reports in Internal Medicine
• Derginin Tarandığı İndeksler: Scopus
• Anahtar Kelimeler: COVID-19, Cytokine release syndrome, Tocilizumab
• Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Cytokine release syndrome (CRS) is a systemic inflammatory response that can be triggered by many factors such as infections. CRS in patients with coronavirus disease 2019 (COVID-19) is life-threatening and can occur very rapidly after COVID-19 diagnosis. Tocilizumab (TCZ), an interleukin-6 (IL-6) inhibitor, may ameliorate the CRS associated with severe COVID-19 and thus improve clinical outcomes. We present a case of life-threatening CRS caused by COVID-19 infection successfully treated with TCZ.